Fibroadenoma is the most common benign tumor of the female breast and usually appears in prepubertal girls and young women, with the peak prevalence in the third decade. They result from ———-. These tumors are ————– and comprised of both glandular epithelium and fibrous tissue. They usually appear as a solitary, discrete, freely movable nodule (1-10 cm in diameter). ———— is mandatory to verify its benign nature.
increased estrogen
encapsulated
Biopsy
Carcinoma of the breast can be classified as ————- or ——— carcinoma (arising from glandular acini).
ductal carcinoma (arising from ductal epithelium)
lobular
Both ductal and lobular carcinoma have ——- precursor stages, termed ————- in which the neoplasm has not penetrated the ——— and thus has not invaded or infiltrated the ————–.
noninvasive
ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS),
basement membrane
connective tissue stroma
D. Portal hypertension
1. Increased pressure of portal blood flow can occur:
prehepatic (obstructive thrombi), intrahepatic (cirrhosis), and post hepatic (right sided heart failure).
D. Portal hypertension
1) ascites (excess fluid in peritoneal cavity-fluid is generally serous in nature), 2) esophageal varices, 3) splenomegaly, 4) hepatic encephalopathy, 5) hypogonadism.
E. Jaundice and cholestasis
Insoluble, toxic
Soluble, nontoxic
benign, self-limiting disease
HAV viremia
Hep A
• ——— of transmission, seen with overcrowding/unsanitary conditions. Ingestion of contaminated water and food
Fecal-oral route
Hep A
• Incubation
2-6 weeks
Hep A
• NO ——- state. No —— disease
carrier
chronic
a. ——- carrier state. Hepatitis B induced liver disease is an important precursor for —————.
asymptomatic
hepatocellular carcinoma
Hep B
• ——- virus
DNA
Hep B
• Incubation —–
4-26 weeks
Hep B
• ————— determines the ultimate outcome. Hepatocyte damage-likely reflects————— to Hepatitis B infected hepatocytes. Optimal outcome is to obtain viral clearance without a lot of collateral damage to liver tissues.
Host immune response
CD8+ cytotoxic T cell damage
Hep B
• Serology:
Remains in blood
Hep B
• Vaccine:
95 % protective Ab response
Hep B
• Increased risk of
hepatocellular response
chronic disease
cirrhosis
persistent infection, chronic hepatitis.
• ———- virus
•
RNA
• Incubation ———-, acute phase is ———
7-8 weeks
asymptomatic
• No vaccine because of ————–
genomic instability
• ———– occurs in approximately 80-85%, and may develop 5 to 20 years later.
Cirrhosis
hepatocellular carcinoma
liver transplantation
interferon and ribavirin
Treatment with ————— now considered curative.
protease and nucleoside inhibitors